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ABSTRACT
OBJECTIVE: The objective of the selective EBM review is to determine whether or not, “Is
curcumin effective at reducing pain in arthritis patients?”
STUDY DESIGN: Review of three, double blind, randomized controlled trials (RCTs),
published between 2012 and 2014, all in English language. The articles compared oral curcumin
to visually matched placebo or accepted standard treatment.
DATA SOURCES: Three RCTs were found using PubMed. All articles were published in peerreviewed journals and selected based on correlation to topic choice, date of publication, and
evaluating POEMs.
OUTCOMES MEASURED: Patient reported pain level, as measured by visual analog scale
(VAS) score.
RESULTS: All three studied demonstrated a statistically significant reduction in patients’ pain
levels in the curcumin group versus the control group. Chandran et al reported a mean change in
baseline pain of 59.9% in the curcumin group, as compared to 49.94% in control group.
Nakagawa et al also demonstrated a statistically significant change in mean from baseline
between curcumin treatment and placebo. Panahi et al similarly found a post-treatment reduction
in VAS to be statistically significant between curcumin and placebo.
CONCLUSION: Based off the data collected from the three RCTs, curcumin is effective in
reducing arthritis pain in patients.
KEY WORDS: curcumin, arthritis
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INTRODUCTION
Osteoarthritis is a chronic degenerative condition of the joints that can cause disability
and loss of function. Hallmarks of the condition include cartilage degeneration, increased
subchondral thickness, osteophyte formation, and mild joint inflammation. The most common
joints affected are knees, hips, interphalangeal joints and lumbosacral spine 5. Rheumatoid
arthritis is a systemic inflammatory disease characterized by synovitis in multiple joints 9. This
paper evaluates three randomized controlled trials (RCTs) comparing the efficacy of oral
curcumin to placebo at reducing arthritis patients’ pain.
Currently 54.4 million United States adults have been diagnosed with a form of arthritis
by a doctor. This represents 22.7% of the adult population of the country. The incidence is
predicted to increase to 26% and by 2040 an estimated 78 million US adults will have a
diagnosis of arthritis3. In 2003 arthritis accounted for $128 billion of health care costs4. Arthritis
visits are extremely common in primary care and physician assistants are frequently responsible
for management of the condition. Arthritis-related complaints account for over 100 million office
visits each year1.
Risk factors for developing arthritis include joint injury, overuse, increased age, female
gender, obesity, family history and race2. As the population ages and obesity affects more
individuals the incidence of arthritis will continue to increase. Treatment for osteoarthritis
includes non-pharmacologic measures such as physical therapy, exercise, joint unloading and
weight loss. Pharmacologic therapies available are acetaminophen, oral or topical NSAIDs,
topical capsaicin, intra-articular steroid injections or opioids. For advanced cases, surgical
treatment such as joint replacement is indicated5. Rheumatoid arthritis treatments may include
oral or intra-articular steroids and DMARDs such as methotrexate or TNF inhibitors 9. A
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concerning factor for treatment of arthritis is long term use of anti-inflammatory agents. Both
osteoarthritis and rheumatoid arthritis have inflammatory components of the disease that
contribute to pain. Risks of long term NSAID use include cardiovascular complications and
gastrointestinal ulcers, while long term corticosteroid use carries significant complications of
bone loss, cataracts and neurological changes. Due to the chronic nature of arthritis it is
important to seek safer alternatives to current treatments, as well as evaluate add-on therapies.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not curcumin is
effecting in reducing pain in arthritis patients.
METHODS
Three randomized controlled trials were used in this review. Adults (over age 18) with
osteoarthritis or rheumatoid arthritis comprise the population of the studies utilized. The
experimental intervention was oral curcumin. Studies varied in dose of curcumin from 180
mg/day to 1500 mg/day. The control group in Chandran et al study was given diclofenac sodium
50 mg6. The control group in Nakagawa et al and Panahi et al received a visually-matched
placebo pill6,7. The outcome evaluated in all three studies was a reduction in pain level, as
demonstrated by VAS score.
All RCTs reviewed were published in peer-reviewed articles, written in English and
found on the PubMed database. The keywords used in searches were “curcumin” and “arthritis.”
The articles were chosen based on relevance to the objective and whether the outcome evaluated
was a POEM. The inclusion criteria were randomized, controlled studies published within the
last ten years. Exclusion criteria included patients under 18 years of age and disease-oriented
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evidence. Reported statistics were mean change from baseline, p-value and independent samples
t-test.
Table 1: Demographics and Characteristics of Included Studies
Study
Chandran,
2012

Type #
Age
Pts (yrs)
RCT 45 1865

Nakagawa, RCT
2014

50

>40

Panahi,
2014

53

<80

RCT

Inclusion
Criteria
RA
diagnosis,
RA
functional
class I/II,
Disease
activity
score>5.1

Primary
medial knee
OA,
KellgrenLawrence
grades II/III
via xray
Degenerative
primary knee
OA mildmoderate
severity;
bilateral OA

Exclusion Criteria

W/D

Interventions

Concurrent treatment with
NSAID/DMARD/antiTNF; Hgb <6.2, creatinine
>1.4 mg/dL; bone/joint
surgery within 8 weeks of
screening or planned <12
weeks after randomization;
fibromyalgia dx; hx TB,
uncontrolled DM, severe
allergic reaction to
medications; pregnant or
nursing; hx of alcohol or
drug abuse
Previous knee surgeries;
knee injection during
study; knee injection
within 2 months of study;
other steroids within 4
weeks of study

7

Curcumin
BCM-95
500mg

9

Theracurmin
containing
180 mg/day of
curcumin

Allergy to curcuminoids;
candidate for joint
replacement; OA
secondary to trauma;
malabsorption disorders;
ESR>20; heart/renal/liver
failure; corticosteroid use
above 10 mg/day in last 3
months; history psych
disorders; intra-articular
injections within last 3
months

13

C3complex®
1500mg/day
with 5-mg
Bioperine®
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OUTCOMES MEASURED
The primary outcome measured in all three studies was change in visual activity scale
score. The patient-oriented outcome addressed in all three studies is patients’ pain levels
indicated by patient marking a line on a scale of 0 (no pain) to 100 (severe pain). Each study
collected initial VAS scores prior to intervention and again after the trial.
RESULTS
Two studies compared oral curcumin with placebo and one with oral curcumin vs.
diclofenac (standard treatment)5,6,7. Panahi et al evaluated the intervention over 6 weeks, while
both Chandran et al and Nakagawa et al evaluated over 8 weeks 5,6,7. Chandran et al was a singleblinded study, while both Nakagawa et al and Panahi et al were double-blinded5,6,7.
The Chandran et al study was conducted in Karala, India and included patients age 18-65
who have been diagnosed with rheumatoid arthritis and disease activity score greater than 5.1 6.
Exclusion criteria for the study included recent treatment for RA, low hemoglobin, elevated liver
enzymes, recent surgery, other significant rheumatologic disease, history of tuberculosis,
pregnancy, and history of alcohol or drug abuse6. Chandran et al evaluated 45 patients randomly
divided into three groups6. The first group received oral curcumin (500mg), the second received
diclofenac sodium (50 mg) and the third received a combination over a period of 8 weeks6. Only
the first two groups will be discussed in this review 6. Of the initial 45 patients, 38 completed the
study and the author did not report reasons for leaving the trial6. At the end of the trial patients
reported their assessment of disease activity by visual analog scale (VAS) with 0 being no pain
and 100 being severe pain. Chandran et al also evaluated patients’ vital signs and laboratory
values bi-weekly for safety6. Results were calculated by change from baseline to endpoint and
the curcumin group was found to have the highest reduction in VAS score6. An ANOVA test
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was used to assess primary outcome of the trial between groups 6. Within the groups an
independent t-test was used to evaluate significance of change from baseline 6. A significant pvalue of <.05 was calculated for change from baseline for this group 6. There was not a significant
difference between curcumin and diclofenac pain reduction percentages, however this
demonstrates similar efficacy to conventional NSAID treatment for rheumatoid arthritis 6. The
diclofenac group had the most adverse events, with three patients reporting side effects, while
curcumin patients reported two adverse events (minor fever and throat infection)6.
Table 2: Patient Outcomes as Evaluated by Mean Change in VAS in Chandran et al
Baseline

End of Treatment

p-value

Curcumin

68.57 17.14

27.5 9.45

<.05

Diclofenac

78.25 11.25

39.17 20.1

<.05

Nakagara et al conducted their study in Japan and included 50 patients with primary
medial knee osteoarthritis7. Exclusion criteria included previous knee surgeries, recent knee
injections or recent steroid treatment7. Patients were randomly divided into two groups, the first
of which received 180 mg of oral curcumin per day and the control received a visually-matched
placebo7. Three subjects in total were lost to follow-up during the study (two from the curcumin
group and one from the control) and three patients dropped out due to adverse effects7. Two
patients in the curcumin group withdrew due to hypertension and redness of the tongue, while
one in the control group felt unwell7. Patients were seen at weeks 2, 4, 6 and 8 for compliance
checks. Patients gave an initial knee pain visual analog scale score and were re-evaluated at the
8-week mark7. 41 patients in total were evaluated and those treated with curcumin had
significantly decreases in their VAS scores from baseline versus the placebo group (p=.023)7.
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The authors opted to exclude patients with low initial VAS scores (<.15) when evaluating the
efficacy of the curcumin, as their pain level was already so low no significant change could be
reported7. The authors were also able to verify the safety of the supplement by evaluating
laboratory values on the patients throughout the study7.
Panahi et al conducted a study in Tehran, Iran including 53 patients with primary
degenerative knee osteoarthritis8. Exclusion criteria included allergy to curcuminoids, OA
secondary to trauma, active inflammatory conditions, and heart, renal or liver failure 8. Patients
were randomly assigned to two groups where one group received curcuminoids 1500 mg/day and
the other received a visually matched placebo8. 40 subjects completed the 6-week trial8. The
remaining 13 patients were lost to follow up8. Patients were evaluated by change in VAS from
baseline to end of treatment8. Panahi et al used paired samples t-tests to compare baseline versus
end-trial values for each parameter8. The two groups were compared using independent samples
t-test8. The authors found significant (p<.001) reduction in VAS score from baseline in the
curcumin group, as well as in comparison to the placebo group 8. There were no serious adverse
events reported, only minor gastrointestinal symptoms with 7 patients in the curcumin group
reporting these and 4 in the placebo cases (no significant difference between the groups) 8.
Table 3: Efficacy of Oral Curcumin in Treating Arthritis Pain
Comparison
p-value
Chandran et al
Change from baseline <.05
Nakgawa et al
Placebo
.023
Panahi et al
Placebo
<.001
DISCUSSION
Rheumatoid arthritis and osteoarthritis are both chronic degenerative conditions for
which patients must be on long term treatments to control pain. The current trouble is that
accepted treatments do not have safe profiles. Acetaminophen can cause liver toxicity, chronic
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NSAID use is associated with ulcers and cardiovascular complications and steroids are
associated with osteoporosis5.
Curcumin is a polyphenol extracted from turmeric. Turmeric has been used as a spice in
food preparations for centuries and thus is recognized as safe7. The anti-inflammatory botanical
inhibits mediators of the inflammatory response including cytokines, chemokines, adhesion
molecules, COX-2 and tissue factor6.
Curcumin in available widely in the United States as a supplement. There is no insurance
coverage and it has not been evaluated by the FDA for use as a treatment for arthritis. For highly
concentrated curcumin formulas there is a significant cost to the patient. As it has not been
evaluated in the United States, it is likely that medical practitioners in the country are not
familiar with the treatment and thus are not likely to recommend curcumin to their arthritis
patients.
The three studies considered in this review all indicate that curcumin is an effective
treatment for arthritis pain, as evidenced by patient’s reported VAS score. Chandran et al
demonstrates similar efficacy between curcumin and diclofenac in rheumatoid arthritis patients,
which is encouraging since diclofenac is an accepted treatment for pain5. Both Nakagara et al
and Panahi et al relay information compared to placebo and note clinically significant
improvement in osteoarthritis symptoms6,7.
While all three studies evaluated the effect of curcumin on a patient’s VAS score,
Chandran et al only evaluated mean change from baseline. They evaluated curcumin and
diclofenac separately and found similar reduction in pain levels between the groups but did not
do a statistical analysis for the comparison5. Chandran et al was also the only study that was
single-blinded5. Nakagawa et al and Panahi et al evaluated mean change and compared the two
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groups to find a significant benefit in treatment with curcumin versus placebo6,7. Also, it should
be noted that all three studies took place in Asia, so there warrants further testing in other
countries. There are genetic components of both arthritis and metabolism of medications and
supplements that could affect the efficacy of curcumin as a treatment. The duration of the three
studies ranged from 6-8 weeks which is an acceptable length of time to evaluate how curcumin
affects pain levels in arthritis patients, however it is not a significant amount of time to determine
disease progression and long term effects of curcumin.

CONCLUSION
The results of this review suggest that curcumin is a safe and effective treatment for
arthritis. While all three studies reported a significant (p<.05) reduction in arthritis pain in
patients treated with oral curcumin, the sample sizes were small5,6,7. It is also important to note
that all took place in Asia, so there should be trials on other ethnicities to determine if the
treatment is effective for the general population of the United States. The trials were of a short
duration so longer studies would be important to conduct in the future that include radiologic
evidence of changes in disease progression, as well as long term side effects of curcumin. In
conclusion, the three trials evaluated in this review indicate curcumin is an effective treatment,
but further evaluation with a larger sample size and longer duration trial is needed to fully
determine the effectiveness of curcumin.
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